Invesco Ltd. Grows Stock Holdings in Amgen Inc. $AMGN

Key Points

• Invesco increased its stake in Amgen (AMGN) by 6.6% in Q3 to 4,467,287 shares—about 0.83% of the company—valued at roughly $1.26 billion.
• Analyst coverage is mixed with a consensus rating of “Hold” and an average price target of $354, though some firms raised targets (Argus to $400) while Jefferies initiated at Hold.
• Amgen beat quarterly estimates (EPS $5.29 vs. $4.76; revenue $9.87B), set FY2026 guidance of 21.60–23.00 EPS, and announced a $2.52 quarterly dividend ($10.08 annual, ~2.7% yield).

Invesco Ltd. lifted its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 6.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,467,287 shares of the medical research company's stock after purchasing an additional 277,031 shares during the quarter. Invesco Ltd. owned about 0.83% of Amgen worth $1,260,668,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in AMGN. Evelyn Partners Investment Management LLP bought a new stake in Amgen in the second quarter worth $32,000. Howard Hughes Medical Institute bought a new position in shares of Amgen during the second quarter valued at $32,000. Cloud Capital Management LLC bought a new position in shares of Amgen during the third quarter valued at $34,000. AXS Investments LLC purchased a new position in shares of Amgen in the 3rd quarter worth about $42,000. Finally, Winnow Wealth LLC bought a new position in Amgen in the 3rd quarter worth about $47,000. Hedge funds and other institutional investors own 76.50% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently commented on AMGN. Jefferies Financial Group initiated coverage on shares of Amgen in a research report on Tuesday. They set a "hold" rating and a $350.00 price objective on the stock. Freedom Capital downgraded shares of Amgen from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 12th. Mizuho increased their price target on shares of Amgen from $280.00 to $295.00 and gave the company an "outperform" rating in a report on Tuesday, February 10th. Argus raised their price target on shares of Amgen from $360.00 to $400.00 and gave the company a "buy" rating in a research report on Friday, February 6th. Finally, Weiss Ratings restated a "buy (b)" rating on shares of Amgen in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Amgen presently has a consensus rating of "Hold" and an average price target of $354.00.

Amgen Stock Performance

AMGN stock opened at $367.79 on Friday. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $391.29. The company has a market cap of $198.26 billion, a P/E ratio of 25.85, a price-to-earnings-growth ratio of 3.75 and a beta of 0.45. The stock's fifty day moving average price is $356.96 and its 200-day moving average price is $324.63.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating analysts' consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.Amgen's revenue was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Friday, May 15th. Amgen's dividend payout ratio is 70.84%.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: MariTide and osteoporosis drug sales cited as a key driver of recent investor enthusiasm; analysts/coverage note product momentum that helped push earlier gains. Amgen: MariTide And Osteoporosis Sales Fuel The Rally
• Positive Sentiment: Operational/production support: Rapid Micro Biosystems reported that Amgen expanded a global Growth Direct system rollout (multi‑system order), signaling investments in manufacturing capacity and process efficiency. Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
• Positive Sentiment: Institutional buying/positioning: Amgen is highlighted as a holding in a large income fund, reflecting demand from dividend/income managers seeking defensive, high‑yield large caps. Starbucks, Amgen, and CVS Help This Income Fund Shine
• Positive Sentiment: Macro/sector support: Prominent market commentators have endorsed large‑cap biotech as resilient growth plays, which supports longer‑term investor interest. Josh Brown: Biotech growth stocks immune to disruption risk
• Neutral Sentiment: Company presentation: A recent Leerink Global Healthcare conference transcript provides updated management commentary — useful for gauging near‑term guidance and pipeline cadence but not an immediate catalyst by itself. Amgen Inc. (AMGN) Presents at Leerink Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Valuation discussion: Coverage pieces assessing whether AMGN is mispriced highlight mixed returns vs. peers — useful context for investors but not a direct price mover. Assessing Whether Amgen (AMGN) Shares Look Mispriced After Recent Mixed Returns
• Neutral Sentiment: Short‑interest data appears to contain errors (reports show zero shares/NaN changes and a 0.0 days-to-cover figure); there’s no clear evidence of meaningful short pressure at present.
• Negative Sentiment: Analyst stance: Jefferies initiated coverage with a Hold recommendation, which can cap momentum relative to a Buy/Outperform narrative and may contribute to near‑term selling pressure. Jefferies initiates coverage of Amgen (AMGN) with hold recommendation

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.